- Home
- TAK
as 12-18-2024 11:43am EST
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
| Founded: | 1781 | Country: | Japan |
| Employees: | N/A | City: | N/A |
| Market Cap: | 42.5B | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 1.27 | EPS Growth: | 49.73 |
| 52 Week Low/High: | $12.58 - $15.08 | Next Earning Date: | 01-30-2025 |
| Revenue: | $31,732,209,416 | Revenue Growth: | 9.43% |
| Revenue Growth (this year): | 4.41% | Revenue Growth (next year): | 1.09% |
Latest Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of) News
TAK Breaking Stock News: Dive into TAK Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Hutchmed to Receive $10 Million Milestone Payment Through Takeda
GlobeNewswire
6 days ago
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
Business Wire
6 days ago
Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas
BioPharma Dive
14 days ago
Novavax sells Czech plant to Novo; Relay licenses out a cancer drug
Pharmaceutical Technology
14 days ago
Takeda licensed for anaemia therapy by Keros Therapeutics
Benzinga
15 days ago
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
MT Newswires
15 days ago
Keros Therapeutics Enters Global Development, License Deal with Takeda Pharmaceutical for Elritercept
GlobeNewswire
15 days ago
Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept
Compare TAK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.